• Je něco špatně v tomto záznamu ?

Trends in allogeneic transplantation for favorable risk acute myeloid leukemia in first remission: a longitudinal study of >15 years from the ALWP of the EBMT

A. Nagler, M. Labopin, U. Salmenniemi, D. Wu, D. Blaise, A. Rambaldi, P. Reményi, E. Forcade, G. Socié, P. Chevallier, P. von dem Borne, D. Burns, C. Schmid, J. Maertens, N. Kröger, G. Bug, M. Aljurf, J. Vydra, K. Halaburda, F. Ciceri, M. Mohty

. 2024 ; 59 (11) : 1563-1576. [pub] 20240820

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, multicentrická studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc25003698
E-zdroje Online Plný text

NLK Free Medical Journals od 1997 do Před 1 rokem
Freely Accessible Science Journals od 1997 do Před 1 rokem
ProQuest Central od 2000-01-01 do Před 1 rokem
Open Access Digital Library od 1997-01-01
Health & Medicine (ProQuest) od 2000-01-01 do Před 1 rokem

Odkazy

PubMed 39164484
DOI 10.1038/s41409-024-02379-z
Knihovny.cz E-zdroje

We assessed outcomes of allogeneic transplantation (HSCT) in favorable risk AML in CR1 over 3 time periods. 1850 patients were included, 2005 to 2009- 222, 2010 to 2014 -392, and 2015 to 2021-1236; 526 with t (8:21), 625 with inv (16), and 699 with NPM1mutFLT3WT. Patients transplanted in 2015-2021 were older (p < 0.0001) with more patients ≥60 years of age (p < 0.0001). The most frequent diagnosis in 2015-2021 was NPM1mutFLT3WT vs. t (8:21) in the 2 earlier periods, (p < 0001). Haploidentical transplants (Haplo) increased from 5.9% to 14.5% (p < 0.0001). Graft-versus-host disease (GVHD) prophylaxis with post-transplant cyclophosphamide (PTCy) was more frequent in 2015-2021 vs. the other 2 periods (p < 0.0001). On multivariate analysis, incidence of total chronic GVHD was reduced in HSCTs performed ≥2015 vs. those performed in 2005-2009, hazard ratio (HR) = 0.74 (95% CI 0.56-0.99, p = 0.046) and GVHD-free, relapse-free survival (GRFS) improved for patients transplanted from 2010-2014 vs. those transplanted in 2005-2009, HR = 0.74 (95% CI 0.56-0.98, p = 0.037). Other HSCT outcomes did not differ with no improvement ≥2015. LFS, OS, and GRFS were inferior in patients with t (8:21) with HR = 1.32 (95% CI 1.03-1.68, p = 0.026), HR = 1.38 (95% CI 1.04-1.83, p = 0.027) and HR = 01.25 (95% CI 1.02-1.53, p = 0.035), respectively. In conclusion, this retrospective analysis of HSCT in patients with favorable risk AML, transplanted over 16 years showed an increased number of transplants in patients ≥60 years, from Haplo donors with PTCy. Most importantly, 3-year GRFS improved ≥2010 and total chronic GVHD reduced ≥2015, with no significant change in other HSCT outcomes.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25003698
003      
CZ-PrNML
005      
20250206104625.0
007      
ta
008      
250121s2024 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1038/s41409-024-02379-z $2 doi
035    __
$a (PubMed)39164484
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Nagler, Arnon $u Division of Hematology, Sheba Medical Center, Tel Hashomer, Israel. arnon.nagler@sheba.health.gov.il $1 https://orcid.org/0000000207631265
245    10
$a Trends in allogeneic transplantation for favorable risk acute myeloid leukemia in first remission: a longitudinal study of >15 years from the ALWP of the EBMT / $c A. Nagler, M. Labopin, U. Salmenniemi, D. Wu, D. Blaise, A. Rambaldi, P. Reményi, E. Forcade, G. Socié, P. Chevallier, P. von dem Borne, D. Burns, C. Schmid, J. Maertens, N. Kröger, G. Bug, M. Aljurf, J. Vydra, K. Halaburda, F. Ciceri, M. Mohty
520    9_
$a We assessed outcomes of allogeneic transplantation (HSCT) in favorable risk AML in CR1 over 3 time periods. 1850 patients were included, 2005 to 2009- 222, 2010 to 2014 -392, and 2015 to 2021-1236; 526 with t (8:21), 625 with inv (16), and 699 with NPM1mutFLT3WT. Patients transplanted in 2015-2021 were older (p < 0.0001) with more patients ≥60 years of age (p < 0.0001). The most frequent diagnosis in 2015-2021 was NPM1mutFLT3WT vs. t (8:21) in the 2 earlier periods, (p < 0001). Haploidentical transplants (Haplo) increased from 5.9% to 14.5% (p < 0.0001). Graft-versus-host disease (GVHD) prophylaxis with post-transplant cyclophosphamide (PTCy) was more frequent in 2015-2021 vs. the other 2 periods (p < 0.0001). On multivariate analysis, incidence of total chronic GVHD was reduced in HSCTs performed ≥2015 vs. those performed in 2005-2009, hazard ratio (HR) = 0.74 (95% CI 0.56-0.99, p = 0.046) and GVHD-free, relapse-free survival (GRFS) improved for patients transplanted from 2010-2014 vs. those transplanted in 2005-2009, HR = 0.74 (95% CI 0.56-0.98, p = 0.037). Other HSCT outcomes did not differ with no improvement ≥2015. LFS, OS, and GRFS were inferior in patients with t (8:21) with HR = 1.32 (95% CI 1.03-1.68, p = 0.026), HR = 1.38 (95% CI 1.04-1.83, p = 0.027) and HR = 01.25 (95% CI 1.02-1.53, p = 0.035), respectively. In conclusion, this retrospective analysis of HSCT in patients with favorable risk AML, transplanted over 16 years showed an increased number of transplants in patients ≥60 years, from Haplo donors with PTCy. Most importantly, 3-year GRFS improved ≥2010 and total chronic GVHD reduced ≥2015, with no significant change in other HSCT outcomes.
650    _2
$a lidé $7 D006801
650    12
$a akutní myeloidní leukemie $x terapie $7 D015470
650    _2
$a lidé středního věku $7 D008875
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a dospělí $7 D000328
650    12
$a transplantace hematopoetických kmenových buněk $x metody $7 D018380
650    _2
$a senioři $7 D000368
650    _2
$a longitudinální studie $7 D008137
650    _2
$a nemoc štěpu proti hostiteli $x prevence a kontrola $x etiologie $7 D006086
650    _2
$a homologní transplantace $x metody $7 D014184
650    _2
$a mladiství $7 D000293
650    _2
$a indukce remise $7 D012074
650    _2
$a nukleofosmin $7 D000090243
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a mladý dospělý $7 D055815
650    _2
$a alografty $7 D064591
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
700    1_
$a Labopin, Myriam $u EBMT Paris study office; Department of Haematology, Saint Antoine Hospital; INSERM UMR 938, Sorbonne University, Paris, France $u Sorbonne University, Department of Haematology, Saint Antoine Hospital; INSERM UMR 938, Paris, France $1 https://orcid.org/0000000345144748
700    1_
$a Salmenniemi, Urpu $u HUCH Comprehensive Cancer Center, Helsinki, Finland
700    1_
$a Wu, Depei $u First Affiliated Hospital of Soochow University, Suzhou, China
700    1_
$a Blaise, Didier $u Programme de Transplantation & Therapie Cellulaire, Marseille, France
700    1_
$a Rambaldi, Alessandro $u Department of Oncology and Hematology, University of Milan and Azienda Socio-Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy
700    1_
$a Reményi, Péter $u Dél-pesti Centrumkórház, Budapest, Hungary
700    1_
$a Forcade, Edouard $u CHU Bordeaux, Hopital Haut-L'évêque, Pessac, France
700    1_
$a Socié, Gérard $u University Paris Cité, INSERM UMR 976, APHP- Saint-Louis Hospital, BMT Unit, Paris, France $1 https://orcid.org/0000000221147533
700    1_
$a Chevallier, Patrice $u CHU Nantes, Nantes, France $1 https://orcid.org/0000000331425581
700    1_
$a von dem Borne, Peter $u Leiden University Medical Center, Leiden, The Netherlands $1 https://orcid.org/0000000274707346
700    1_
$a Burns, David $u University Hospital Birmingham NHS Trust, Stoke, UK
700    1_
$a Schmid, Christoph $u Klinikum Augsburg, Augsburg, Germany $1 https://orcid.org/000000017070487X
700    1_
$a Maertens, Johan $u University Hospital Gasthuisberg, Leuven, Belgium $1 https://orcid.org/0000000342575980
700    1_
$a Kröger, Nicolaus $u University Medical Center Hamburg, Hamburg, Germany
700    1_
$a Bug, Gesine $u Goethe-Universitaet, Frankfurt Main, Germany $1 https://orcid.org/000000032359131X
700    1_
$a Aljurf, Mahmoud $u King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia $1 https://orcid.org/0000000339427370
700    1_
$a Vydra, Jan $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic $1 https://orcid.org/0000000242743895
700    1_
$a Halaburda, Kazimierz $u Institute of Hematology and Transfusion Medicine, Warsaw, Poland
700    1_
$a Ciceri, Fabio $u IRCCS Osspedale San Raffaele, Vita-Salute San Raffaele University Haematology and BMT, Milano, Italy $1 https://orcid.org/0000000308730123
700    1_
$a Mohty, Mohamad $u EBMT Paris study office; Department of Haematology, Saint Antoine Hospital; INSERM UMR 938, Sorbonne University, Paris, France $u Sorbonne University, Department of Haematology, Saint Antoine Hospital; INSERM UMR 938, Paris, France $1 https://orcid.org/000000027264808X $7 xx0317729
773    0_
$w MED00000834 $t Bone marrow transplantation $x 1476-5365 $g Roč. 59, č. 11 (2024), s. 1563-1576
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39164484 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250121 $b ABA008
991    __
$a 20250206104620 $b ABA008
999    __
$a ok $b bmc $g 2263453 $s 1239705
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 59 $c 11 $d 1563-1576 $e 20240820 $i 1476-5365 $m Bone marrow transplantation $n Bone Marrow Transplant $x MED00000834
LZP    __
$a Pubmed-20250121

Najít záznam

Citační ukazatele

Možnosti archivace